MX377387B - Nuevo compuesto para usarse en el tratamiento de fibrosis quística. - Google Patents
Nuevo compuesto para usarse en el tratamiento de fibrosis quística.Info
- Publication number
- MX377387B MX377387B MX2016014756A MX2016014756A MX377387B MX 377387 B MX377387 B MX 377387B MX 2016014756 A MX2016014756 A MX 2016014756A MX 2016014756 A MX2016014756 A MX 2016014756A MX 377387 B MX377387 B MX 377387B
- Authority
- MX
- Mexico
- Prior art keywords
- cftr
- trimethylphenylimino
- pyrimido
- isoquinolin
- carbamoyl
- Prior art date
Links
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 4
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- CSOBIBXVIYAXFM-UHFFFAOYSA-N rpl-554 Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2CCNC(N)=O)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C CSOBIBXVIYAXFM-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000009890 sinusitis Diseases 0.000 abstract 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000024632 Idiopathic bronchiectasis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000007466 Male Infertility Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010033649 Pancreatitis chronic Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 210000001177 vas deferen Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona un compuesto para uso en el tratamiento o prevención de una enfermedad o afección seleccionada de fibrosis quística, enfermedad pulmonar obstructiva crónica (COPD), asma, enfermedad pulmonar leve, bronquitis, bronquiectasia, bronquiectasia idiopática, aspergilosis broncopulmonar alérgica, sinusitis, rinosinusitis, síndrome metabólico relacionado con CFTR (CRMS), pancreatitis, pancreatitis crónica idiopática y síndrome de Sjörgren, o para su uso en la prevención de la infertilidad masculina causada por la ausencia congénita de los conductos deferentes, en un paciente mediante la modulación de la actividad de CFTR, cuyo compuesto es 9,10-dimetoxi-2-(2,4,6-trimetilfenilimino)-3-(N-carbamoil-2-aminoetil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]isoquinolin-4-ona o una sal de adición de ácido farmacéuticamente aceptable del mismo. La invención también proporciona una composición que comprende (i) 9,10-dimetoxi-2-(2,4,6-trimetilfenilimino)-3-(N-carbamoil-2-aminoetil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]isoquinolin-4-ona o una sal de adición de ácido farmacéuticamente aceptable del mismo y (ii) un antagonista del receptor de leucotrieno. La invención también proporciona una composición que comprende (i) 9,10-dimetoxi-2-(2,4,6-trimetilfenilimino)-3-(N-carbamoil-2-aminoetil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]isoquinolin-4-ona o una sal de adición de ácido farmacéuticamente aceptable del mismo y (ii) un potenciador de CFTR o un corrector de CFTR.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1408384.4A GB201408384D0 (en) | 2014-05-12 | 2014-05-12 | New treatment |
| GBGB1417719.0A GB201417719D0 (en) | 2014-10-07 | 2014-10-07 | New treatment |
| PCT/GB2015/051377 WO2015173551A1 (en) | 2014-05-12 | 2015-05-11 | New treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014756A MX2016014756A (es) | 2017-03-23 |
| MX377387B true MX377387B (es) | 2025-03-10 |
Family
ID=53264683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014756A MX377387B (es) | 2014-05-12 | 2015-05-11 | Nuevo compuesto para usarse en el tratamiento de fibrosis quística. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10864213B2 (es) |
| EP (2) | EP3142701B1 (es) |
| AU (1) | AU2015261239B2 (es) |
| CA (1) | CA2948620C (es) |
| CY (2) | CY1120550T1 (es) |
| DK (2) | DK3231444T3 (es) |
| ES (2) | ES2682105T3 (es) |
| HU (1) | HUE048020T2 (es) |
| IL (1) | IL248856B (es) |
| MX (1) | MX377387B (es) |
| PL (2) | PL3231444T3 (es) |
| PT (2) | PT3142701T (es) |
| RU (1) | RU2688191C2 (es) |
| SI (2) | SI3142701T1 (es) |
| WO (1) | WO2015173551A1 (es) |
| ZA (1) | ZA201607705B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2745977C2 (ru) | 2010-04-22 | 2021-04-05 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| SG10201913575VA (en) | 2014-04-15 | 2020-02-27 | Vertex Pharma | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| SI3142701T1 (en) | 2014-05-12 | 2018-08-31 | Verona Pharma Plc | NEW TREATMENT |
| HUE055527T2 (hu) | 2014-09-15 | 2021-12-28 | Verona Pharma Plc | RPL554-t tartalmazó folyékony inhalációs készítmény |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
| GB2578093B (en) | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB201911517D0 (en) * | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| EP4081310B1 (en) * | 2019-12-26 | 2026-02-11 | National Jewish Health | Lubiprostone combinations for use in treating cystic fibrosis transmembrane conductance regulator (cftr) dysfunction |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
| WO2025093848A1 (en) | 2023-11-01 | 2025-05-08 | Verona Pharma Plc | Ensifentrine for treating bronchiectasis |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE455946B (sv) | 1986-10-20 | 1988-08-22 | Trion Forskning & Utveckling | Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| AU2178392A (en) | 1991-06-12 | 1993-01-12 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| AU675633B2 (en) | 1991-12-18 | 1997-02-13 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| JP2002512183A (ja) | 1998-04-18 | 2002-04-23 | グラクソ グループ リミテッド | 医薬用エアゾール製剤 |
| GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| CN100415743C (zh) | 1999-03-31 | 2008-09-03 | 韦尔纳利斯有限公司 | 嘧啶并[6,1-a] 异喹啉-4-酮衍生物 |
| ES2193069T3 (es) | 1999-04-14 | 2003-11-01 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol. |
| MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| HRP20150288T1 (hr) | 2008-11-06 | 2015-04-24 | Vertex Pharmaceuticals Incorporated | Modulatori atp-vezujuä†ih kasetnih transportera |
| BR112012005503B1 (pt) | 2009-09-11 | 2021-10-13 | Chiesi Farmaceutici S.P.A. | Derivados de isoxazolidina |
| AR082601A1 (es) * | 2010-08-09 | 2012-12-19 | Verona Pharma Plc | Formas cristalinas de compuestos de pirimido[6,1-a]isoquinolin-4-ona |
| WO2012069275A1 (en) | 2010-11-26 | 2012-05-31 | Chiesi Farmaceutici S.P.A. | Glycine derivatives and their use as muscarinic receptor antagonists |
| WO2012107364A1 (en) | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
| EP2744493A1 (en) * | 2011-08-18 | 2014-06-25 | Shire AG | Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy |
| JP2015511583A (ja) * | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| WO2014140747A2 (en) | 2013-03-14 | 2014-09-18 | Lincoln Global, Inc. | Systems and methods of exporting or using welding sequencer data for external systems |
| US9700558B2 (en) | 2013-03-15 | 2017-07-11 | Verona Pharma Plc | Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist |
| SI3142701T1 (en) | 2014-05-12 | 2018-08-31 | Verona Pharma Plc | NEW TREATMENT |
| HUE055527T2 (hu) | 2014-09-15 | 2021-12-28 | Verona Pharma Plc | RPL554-t tartalmazó folyékony inhalációs készítmény |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB202002786D0 (en) | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
-
2015
- 2015-05-11 SI SI201530328T patent/SI3142701T1/en unknown
- 2015-05-11 ES ES15724354.4T patent/ES2682105T3/es active Active
- 2015-05-11 MX MX2016014756A patent/MX377387B/es active IP Right Grant
- 2015-05-11 EP EP15724354.4A patent/EP3142701B1/en active Active
- 2015-05-11 PL PL17174446T patent/PL3231444T3/pl unknown
- 2015-05-11 DK DK17174446.9T patent/DK3231444T3/da active
- 2015-05-11 EP EP17174446.9A patent/EP3231444B1/en active Active
- 2015-05-11 AU AU2015261239A patent/AU2015261239B2/en active Active
- 2015-05-11 WO PCT/GB2015/051377 patent/WO2015173551A1/en not_active Ceased
- 2015-05-11 SI SI201531105T patent/SI3231444T1/sl unknown
- 2015-05-11 DK DK15724354.4T patent/DK3142701T3/en active
- 2015-05-11 RU RU2016148447A patent/RU2688191C2/ru active
- 2015-05-11 ES ES17174446T patent/ES2773142T3/es active Active
- 2015-05-11 US US15/310,693 patent/US10864213B2/en active Active
- 2015-05-11 PL PL15724354T patent/PL3142701T3/pl unknown
- 2015-05-11 HU HUE17174446A patent/HUE048020T2/hu unknown
- 2015-05-11 PT PT15724354T patent/PT3142701T/pt unknown
- 2015-05-11 PT PT171744469T patent/PT3231444T/pt unknown
- 2015-05-11 CA CA2948620A patent/CA2948620C/en active Active
-
2016
- 2016-11-08 ZA ZA2016/07705A patent/ZA201607705B/en unknown
- 2016-11-09 IL IL248856A patent/IL248856B/en active IP Right Grant
-
2018
- 2018-08-09 CY CY20181100831T patent/CY1120550T1/el unknown
-
2020
- 2020-02-19 CY CY20201100153T patent/CY1122748T1/el unknown
- 2020-11-16 US US17/099,598 patent/US11759467B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3142701T (pt) | 2018-10-18 |
| ES2773142T3 (es) | 2020-07-09 |
| EP3142701B1 (en) | 2018-06-27 |
| ES2682105T3 (es) | 2018-09-18 |
| US10864213B2 (en) | 2020-12-15 |
| PL3231444T3 (pl) | 2020-05-18 |
| AU2015261239B2 (en) | 2020-02-27 |
| PL3142701T3 (pl) | 2018-11-30 |
| CY1122748T1 (el) | 2021-03-12 |
| MX2016014756A (es) | 2017-03-23 |
| WO2015173551A1 (en) | 2015-11-19 |
| US11759467B2 (en) | 2023-09-19 |
| CA2948620C (en) | 2023-01-24 |
| RU2688191C2 (ru) | 2019-05-21 |
| RU2016148447A (ru) | 2018-06-19 |
| DK3231444T3 (da) | 2020-03-16 |
| US20170112839A1 (en) | 2017-04-27 |
| SI3231444T1 (sl) | 2020-04-30 |
| ZA201607705B (en) | 2020-05-27 |
| EP3231444A1 (en) | 2017-10-18 |
| AU2015261239A1 (en) | 2016-12-01 |
| PT3231444T (pt) | 2020-03-05 |
| CA2948620A1 (en) | 2015-11-19 |
| US20210106585A1 (en) | 2021-04-15 |
| EP3231444B1 (en) | 2019-12-18 |
| HUE048020T2 (hu) | 2020-05-28 |
| IL248856A0 (en) | 2017-01-31 |
| RU2016148447A3 (es) | 2018-12-27 |
| EP3142701A1 (en) | 2017-03-22 |
| SI3142701T1 (en) | 2018-08-31 |
| DK3142701T3 (en) | 2018-08-13 |
| IL248856B (en) | 2020-07-30 |
| CY1120550T1 (el) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377387B (es) | Nuevo compuesto para usarse en el tratamiento de fibrosis quística. | |
| SA519402319B1 (ar) | Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز | |
| NZ600707A (en) | 4-oxo-1h-quinoline-3-carboxamides as modulators of atp-binding cassette transporters | |
| MY198769A (en) | Substituted heterocyclic derivatives as cdk inhibitors | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
| JP2015199769A5 (es) | ||
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| UA110310C2 (uk) | Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar) | |
| PH12015500460A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| PH12018501236A1 (en) | Pharmaceutical composition comprising a potent inhibitor urat1 | |
| MX2021005207A (es) | Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida. | |
| TN2016000556A1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| JP2017537954A5 (es) | ||
| WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
| PH12016502246A1 (en) | Carboxamide derivatives | |
| MX393779B (es) | Orvepitant para el tratamiento de la tos cronica | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| WO2013117503A3 (en) | Pi3k inhibitors for treating fibrotic diseases | |
| JOP20200127A1 (ar) | مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية | |
| AU2018276273A1 (en) | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | |
| EA029678B9 (ru) | Четвертичные соли пиперидиния | |
| TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
| EA201990481A1 (ru) | Тройная комбинация обратных агонистов рецептора гистамина-3, ингибиторов ацетилхолинэстеразы и антагониста рецептора nmda | |
| PH12020550932A1 (en) | Compositions and methods for treating or preventing vasomotor symptoms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |